Paris, France, January 2, 2017 Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 31 December 2016 the following assets appeared on...
Half-yearly report on the liquidity contract with Gilbert Dupont
read more
Search Results
PERSEE Study demonstrates applicability of Cellvizio in surgical interventions for digestive cancers, triggering milestone payment from BpiFrance
Results from PERSEE Study Published in Surgical Endoscopy and European Journal of Gastroenterology & Hepatology Mauna Kea Technologies receives...
Mauna Kea Technologies secures an Equity Financing Facility
Click to read more
Mauna Kea Technologies Reports third quarter 2016 Sales
Click to read more
Reimbursement increases of 131% for hospitals and 86% for ambulatory surgical centers for key Cellvizio procedures
Click to read more
Cellvizio®’s strong clinical efficacy in the prevention of certain pancreatic cancers confirmed by positive results from CONTACT study presented at UEGW 2016
Leading American clinical researchers launch ground-breaking study of Cellvizio for pediatric cardiac surgery
Click to read more
Announcing a new international society dedicated to advancing the practice of endomicroscopy
Click to read more
Continued New York Area Momentum with Cellvizio® Placement at The Mount Sinai Hospital
Click to read more
Cellvizio® endorsed by the American Society of General Surgeons as integral to the care of patients with Gastroesophageal Reflux Disease (GERD) and Barrett’s Esophagus
Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform,...
Cellvizio® Placement at Florida Hospital Center for Interventional Endoscopy
Click to read more
Mauna Kea Technologies announces the completion of a €4.4 million equity financing
Click to read more